- Home
- YHGJ vs RLMD Comparison
YHGJ vs RLMD Comparison
Compare YHGJ & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | RLMD |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 319.0M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | YHGJ | RLMD |
|---|---|---|
| Price | $4.16 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 19.6K | ★ 907.9K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,377,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $3.37 | $0.24 |
| 52 Week High | $12.70 | $5.12 |
Technical Indicators
Market Signals| Indicator | YHGJ | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 53.59 |
| Support Level | $3.53 | $3.98 |
| Resistance Level | $3.99 | $4.99 |
| Average True Range (ATR) | 0.28 | 0.34 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 54.78 | 40.60 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.